10x Genomics, Inc. (TXG) Cash Flow Statement
10x Genomics, Inc. (TXG) generated $127.1M of operating cash flow over the twelve months to 2026-06-30, spent $5.6M on capital expenditure and had free cash flow of $121.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TXG10x Genomics, Inc.Follow TXG — free
—
Price chart with a free account
- Market cap
- 9.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.03 | -0.22 | -0.02 | -0.03 | -0.02 | 0.01 | 0.14 | 0.13 | |
| Capital expenditure | 0.04 | 0.04 | 0.10 | 0.13 | 0.05 | 0.01 | 0.01 | -0.01 | |
| Free cash flow | -0.01 | -0.25 | -0.12 | -0.17 | -0.06 | -0.01 | 0.13 | 0.12 | |
| Stock-based compensation | 0.01 | 0.05 | 0.10 | 0.14 | 0.17 | 0.14 | 0.11 | — |
USD billions · SEC XBRL
10x Genomics, Inc. — questions
- What is 10x Genomics, Inc.'s operating cash flow?
- $127.1M over the twelve months to 2026-06-30.
- How much does 10x Genomics, Inc. spend on capital expenditure?
- $5.6M over the twelve months to 2026-06-30.
- What is 10x Genomics, Inc.'s free cash flow?
- $121.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from 10x Genomics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.